When Charlotta Topelius and Niklas Sandler founded CurifyLabs in 2021, they were chasing a peculiar problem: the painstaking process by which pharmacists mix custom medications by hand, one patient at a time. Now, with $14 million in fresh capital and a growing network of U.S. pharmacy partners, the Helsinki-based startup thinks it has cracked the code on automating what's long been a decidedly analog corner of healthcare.
The Series A round, announced in July 2026, brought together an unusual coalition. Oslo's Sandwater and Stockholm's HealthCap co-led the investment, joined by Tesi—the Finnish state's industrial investment arm—and Lifeline Ventures, an early backer. More intriguing, perhaps: participation from U.S.-based customers and employees, a signal that CurifyLabs' technology has moved beyond pilot programs into daily pharmacy operations.
The company now claims a presence in pharmacies across 21 U.S. states. It's opened a Jacksonville, Florida office to support that footprint, complementing its European base in Helsinki and smaller outposts in Germany and Texas.
Automating the Art of Compounding
CurifyLabs is targeting non-sterile compounding, the specialized practice of preparing customized medications—think tailored hormone doses, pediatric formulations in flavored suspensions, or veterinary prescriptions for animals of unusual sizes. It's a niche that's escaped much of the automation wave that swept through other parts of pharmaceutical production.
The startup's answer is what it calls the PharmaPrinter, a robotic device that marries 3D printing concepts with pharmaceutical precision. The system relies on proprietary software, pre-manufactured ingredient bases (produced under Good Manufacturing Practice standards), and built-in quality controls. In January, the company unveiled PharmaPrinter Aurum, which it says can outpace manual compounding by up to nine times.
Whether that speed translates to adoption at scale remains an open question. The pharmacy profession has historically approached automation of clinical processes with caution, and regulatory scrutiny of compounding has intensified since a deadly meningitis outbreak in 2012 traced to contaminated steroids from a Massachusetts compounding facility.
CurifyLabs appears to be threading that needle carefully. Its platform holds ISO 13485 certification—the medical device quality standard—and aligns with FDA 503A and 503B frameworks for non-sterile compounding, as well as USP <795>, the revised U.S. Pharmacopeia chapter that took effect in late 2023 and tightened requirements around beyond-use dating and environmental monitoring.
According to the company, its systems now compound thousands of doses daily across its pharmacy network. That's a notable uptick, though still a small fraction of the broader U.S. compounding market, which industry analysts at Grand View Research project will approach $7.18 billion by 2030.
Following the Regulatory Tailwinds
The timing may be right. U.S. compounding pharmacies face a confluence of pressures: stricter compliance mandates, a chronic shortage of pharmacy technicians, and surging demand for personalized medications—particularly in pediatrics, veterinary care, and the booming hormone replacement therapy segment.
CurifyLabs is betting that automation offers a way out, or at least a way forward. The fresh Series A capital will fund expansion of U.S. operations, bolster supply chain infrastructure, and deepen customer support—all while continuing product development. It's a significant step up from the company's €6.7 million raise in May 2025, which was led by Springvest and included a €1 million loan from Business Finland, the state innovation funding agency.
Topelius, the CEO, has a background in pharmacy; her co-founder Sandler brings academic heft as a professor of pharmaceutical technology with more than 100 peer-reviewed publications. The founding team has grown to somewhere between 11 and 50 employees, according to LinkedIn—a wide range that likely reflects a mix of full-time staff and contractors as the company scales.
For now, CurifyLabs occupies an unusual middle ground: too niche to attract the attention of big pharma, but potentially valuable enough to reshape a corner of healthcare that's long operated out of sight. Whether robotic compounding becomes industry standard or remains a specialized tool will depend, in no small part, on whether pharmacists—and their patients—trust machines to do work that's always been done by hand.
